GRCL Gracell Biotechnologies Inc. ADRs
Gracell Biotechnologies is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.
$1.97 -0.01 (-0.51%)
As of 03/27/2023 10:31:05 EST IEX book CBOE book
Security Information
Category1: US Equity
Category2: ADRs
Category3: Micro cap
GICS sector: Health Care
Industry: Biotechnology
Index country: China
Country of incorporation:
IPO date: 01/08/2021
Outstanding shares: 67,685,014
Average volume: 73,290
Market cap: $139,431,129
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Annual filings: 20-F
Sedol: BM90J85
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%